Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
Medtronic has lined up a whole pipeline of new devices – and it will need them.
The good times continue to roll for big cap device makers, with two companies doubling their market value, and not a single share price fall.
The market for minimally invasive aortic implants is sewn up – can a tiny private group find a way in?
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.
Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.